Beijing Tiantan Biological Products Corporation Limited Class A

Beijing Tiantan Biological Products Corporation Limited Class A

SSSE:600161
12.02
CNY
-0.11
(-0.91%)
0.48EPS
36.10P/E
24.90BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.01
1.01
0.93
1.17
1.38
1.63
1.83
1.91
2.12
2.14
2.61
3.04
3.11
2.77
Basic EPS, GAAP
0.21
0.07
0.01
0.14
0.65
0.28
0.34
0.35
0.39
0.44
0.56
0.78
0.55
0.35
Free Cash Flow per Basic Share
0.01
0.01
0.1
0.12
-0.04
0.21
0.06
0.05
-0.08
-0.11
0.66
-0.12
-0.13
- -
Dividend per Share
0.06
0.08
0.07
0.06
0.11
0.08
0.03
0.05
0.08
0.08
0.05
0.12
0.25
- -
Book Value per Share
1.07
1.07
1.07
1.3
2.03
1.87
2.18
2.5
4.07
4.45
4.97
5.63
5.93
6
Tangible Book Value per Share
0.95
0.96
0.97
1.13
1.85
1.65
1.93
2.22
3.65
3.89
4.35
4.68
4.92
4.95
Basic Weighted Avg Shares
1,811
1,800
1,748
1,822
1,802
1,797
1,796
1,804
1,940
1,995
1,982
1,986
1,983
2,007
Sales/Revenue/Turnover
1,837
1,827
1,618
2,138
2,483
2,931
3,282
3,446
4,112
4,261
5,180
6,032
6,168
5,555
Operating Margin (%)
32.6
25.25
22.59
23.7
31.99
29.21
31.34
31.16
28.81
31.28
33.25
41.8
30.68
22.89
Depreciation Expense
92
111
196
215
169
130
128
133
157
180
268
332
425
- -
Net Income, GAAP
372
128
10
257
1,173
509
611
639
760
881
1,110
1,549
1,091
700
Effective Tax Rate (%)
15.6
25.5
41.61
20
10.47
15.21
14.3
14.64
13.88
15.54
16.08
17.08
18.26
21.42
Profit Margin (%)
20.26
7.03
0.62
12.01
47.24
17.38
18.62
18.55
18.48
20.67
21.42
25.68
17.69
12.6
Working Capital
100
-471
335
805
3,244
2,951
3,394
3,699
6,736
6,113
6,290
6,602
7,238
7,455
LT Debt
1,459
1,044
1,780
1,912
200
231
401
503
384
279
24
45
68
63
Total Equity
2,176
2,218
2,236
2,622
4,450
4,347
5,177
6,031
10,267
11,356
12,754
14,533
15,316
15,545
Return on Invested Capital (%)
11.31
4.61
2.28
5.87
27.9
15.37
17.4
14.95
12.02
10.62
12.21
15.31
9.9
- -
Return on Capital (%)
7.85
2.74
-0.5
6.26
20.27
6.12
6.46
5.42
5.14
4.96
5.81
7.23
4.64
- -
Return on Common Equity (%)
21.38
6.64
0.51
11.99
39.04
14.47
16.72
15.11
12.09
10.46
11.92
14.78
9.54
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
21
84
16
LT Borrowings
- -
- -
- -
LT Finance Leases
71
68
63
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,977
1,977
1,977
Market Capitalization
29,878
22,898
24,895

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,353
8,742
8,502
Cash, Cash Equivalents & STI
1,892
2,168
1,901
Accounts Receivable, Net
1,343
1,546
1,477
Inventories
4,148
4,127
4,256
Total Current Liabilities
947
1,252
1,047
Payables & Accruals
- -
- -
- -
ST Debt
21
84
16
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.27%
22.5%
5.39%
Free Cash Flow
-179%
-199.99%
7.73%
Net Income, GAAP
287.02%
14.17%
-29.59%
Sales/Revenue/Turnover
14.65%
12.65%
2.26%
Total Cash Common Dividend
33.64%
59.01%
100%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,222
1,619
1,232
1,959
6,032
2025
1,318
1,793
- -
1,703
6,168
2026
1,142
1,454
1,257
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.21
0.16
0.25
0.78
2025
0.12
0.2
- -
0.14
0.55
2026
0.06
0.09
0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.12
2025
- -
- -
- -
- -
0.25
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hui Chuan Yang
Full Time Employees
5,205
Sector
Health technology
Industry
Biotechnology
Address
No.B2 Shuangqiao Road Beijing BE China 100024
IPO Date
Jun 16, 1998
Business
Beijing Tiantan Biological Products Co., Ltd. specializes in the discovery, production, and distribution of essential biopharmaceutical products across China. The company's portfolio encompasses a wide array of plasma-derived treatments, including human albumin, various immunoglobulins like intravenous, hepatitis B, tetanus, and rabies types, alongside critical coagulation factors such as Factor VIII and prothrombin complex. Additionally, it develops recombinant products and a selection of preventive vaccines. Established in 1998 and based in Beijing, China, the company is recognized as a leader within the Chinese blood product sector, commanding the largest plasma collection volume in the domestic market, reaching 2,415 tons in 2023 and accounting for 20% of the market share. Beijing Tiantan Biological is a subsidiary operating under China National Biotec Group Company Limited, itself a part of Sinopharm, and holds a significant role in national blood product reserves. Recent innovations include the approval of its fourth-generation 10% Intravenous Immunoglobulin, which utilizes a chromatography process, and the marketing authorization for its recombinant human coagulation factor VIII for injection.